CooperCompanies Q2 revenue misses, stock falls 16.8%

CooperCompanies (NASDAQ:COO) reported second-quarter CY2026 revenue of $1.07 billion, a flat year-on-year result that came in 2.9% below analyst consensus. The company’s adjusted earnings per share of $1.15 exceeded estimates by 2.7%, driven by a 20.8% operating margin that improved from 16.6% in the prior year. Despite the profit beat, the stock dropped 16.8% following the release, reflecting investor concern over top-line softness and revised outlooks.

Management lowered full-year revenue guidance to a midpoint of $4.24 billion, a 1.5% reduction from the previous target of $4.30 billion. Concurrently, full-year adjusted EPS guidance was trimmed to $4.53, down 1.9%. The company cited a strategic reduction in U.S. channel inventory at CooperVision as a key factor weighing on current results, with effects expected to extend into the fourth quarter.

Inventory adjustments weigh on vision segment

CEO Al White noted that while CooperSurgical delivered solid fertility growth and the company recorded record free cash flow, the CooperVision division faced headwinds. The deliberate drawdown of U.S. channel inventory reduced reported sales for the period. White stated that this inventory adjustment will continue to impact Q4 results, indicating a temporary suppression of revenue rather than a structural demand collapse.

Organic revenue, which excludes acquisitions and currency effects, grew just 1% year-on-year, missing market expectations. This slowdown follows a two-year annualized growth rate of 5.5%, which is below the company’s five-year compounded annual growth rate of 8.3%. The deceleration in core organic growth signals softening demand in key consumer health categories, despite the company’s broader portfolio resilience.

Profitability improves despite revenue miss

The company’s non-GAAP profit margin expanded significantly, with operating margin rising to 20.8% from 16.6% in the same quarter last year. This efficiency gain allowed CooperCompanies to outperform earnings estimates even as sales lagged. The favorable completion of a significant tax matter also contributed to the stronger profit profile, offsetting the revenue shortfall in the vision care segment.

Market reaction reflects guidance cut

Investors penalized the stock heavily, with shares falling 16.8% to reflect the lowered full-year outlook. The market capitalization stood at $13.2 billion at the time of the report. Although sell-side analysts project 5.3% revenue growth over the next 12 months, exceeding the sector average, the immediate guidance cut and inventory overhang created significant uncertainty near-term. The company remains focused on profitable growth and disciplined capital allocation following its strategic review.